Want to join the conversation?
$BIIB said aducanumab, its investigational treatment for early Alzheimer's disease, was granted Fast Track designation by the U.S. FDA. Aducanumab is being evaluated in 2 Phase 3 studies, ENGAGE and EMERGE, to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in people with early Alzheimer's disease.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.